Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Acquired Syphilis With Anemia and Leukoerythroblastic Reaction: A Case Report.

Mantripragada KC, Rizk SF, Reagan JL, LeGolvan M.

Ann Intern Med. 2016 Aug 2;165(3):226-7. doi: 10.7326/L15-0527. No abstract available.

PMID:
26999776
2.

Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.

Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, Reagan JL, Mega A, Khurshid H, Bartley C, Lombardo A, Rossiter R, Papa A, Bakalarski P, Safran H.

J Oncol Pract. 2016 Apr;12(4):e396-404. doi: 10.1200/JOP.2015.008433.

PMID:
26907448
3.

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia.

Reagan JL, Fast LD, Nevola M, Mantripragada K, Mulder A, Claas FH, Rosati K, Schumacher A, Safran H, Young CT, Quesenberry MI, Winer ES, Butera JN, Quesenberry PJ.

Blood Cancer J. 2015 Dec 4;5:e371. doi: 10.1038/bcj.2015.100. No abstract available.

4.

Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.

Reagan JL, Sullivan MR, Winer ES, Lansigan F, Cardin MS, Castillo JJ.

Leuk Res. 2015 Aug;39(8):812-7. doi: 10.1016/j.leukres.2015.04.015.

PMID:
26045177
5.

Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.

Castillo JJ, Reagan JL, Sikov WM, Winer ES.

Br J Haematol. 2015 May;169(3):352-5. doi: 10.1111/bjh.13300.

PMID:
25612847
6.

Adoptive immunotherapy for myeloid malignancies.

Reagan JL.

Leuk Suppl. 2014 Dec;3(Suppl 1):S21-2. doi: 10.1038/leusup.2014.12. No abstract available.

7.

Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.

Reagan JL, Castillo JJ.

Future Oncol. 2014 May;10(7):1147-55. doi: 10.2217/fon.14.73. Review.

PMID:
24947256
8.

Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing.

Reagan JL, Ingham RR 2nd, Dalia S, Butera JN, Sweeney JD.

Thromb Res. 2014 Jul;134(1):90-2. doi: 10.1016/j.thromres.2014.04.030.

PMID:
24830900
9.

Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies.

Castillo JJ, Reagan JL, Bishop KD, Apor E.

Br J Haematol. 2014 May;165(3):300-15. doi: 10.1111/bjh.12788. Review.

PMID:
24533596
10.

Advances in cellular therapy for the treatment of leukemia.

Mantripragada K, Reagan JL, Quesenberry PJ, Fast LD.

Discov Med. 2014 Jan;17(91):15-24. Review.

11.

Primary refractory Hodgkin lymphoma: limited options and poor survival--but not always.

Gavini A, Reagan JL, Winer ES, Castillo JJ.

Am J Hematol. 2014 Aug;89(8):853-7. doi: 10.1002/ajh.23660. No abstract available.

12.

Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies.

Castillo JJ, Ingham RR, Reagan JL, Furman M, Dalia S, Mitri J.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):122-30. doi: 10.1016/j.clml.2013.10.005.

PMID:
24360912
13.

The St. Louis African American health-heart study: methodology for the study of cardiovascular disease and depression in young-old African Americans.

Bruchas RR, de Las Fuentes L, Carney RM, Reagan JL, Bernal-Mizrachi C, Riek AE, Gu CC, Bierhals A, Schootman M, Malmstrom TK, Burroughs TE, Stein PK, Miller DK, Dávila-Román VG.

BMC Cardiovasc Disord. 2013 Sep 8;13:66. doi: 10.1186/1471-2261-13-66.

14.

Multiple myeloma-induced hyperammonemic encephalopathy: an entity associated with high in-patient mortality.

Pham A, Reagan JL, Castillo JJ.

Leuk Res. 2013 Oct;37(10):1229-32. doi: 10.1016/j.leukres.2013.07.014. Review.

PMID:
23932549
15.

Cellular immunotherapy for refractory hematological malignancies.

Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ.

J Transl Med. 2013 Jun 19;11:150. doi: 10.1186/1479-5876-11-150.

16.

Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies.

Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J.

Blood. 2012 May 24;119(21):4845-50. doi: 10.1182/blood-2011-06-362830.

17.

Why is my patient neutropenic?

Reagan JL, Castillo JJ.

Hematol Oncol Clin North Am. 2012 Apr;26(2):253-66, vii. doi: 10.1016/j.hoc.2012.02.003.

PMID:
22463826
18.

Nonengraftment haploidentical cellular therapy for hematologic malignancies.

Reagan JL, Fast LD, Winer ES, Safran H, Butera JN, Quesenberry PJ.

Adv Hematol. 2012;2012:784213. doi: 10.1155/2012/784213.

19.

Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies.

Castillo JJ, Reagan JL, Ingham RR, Furman M, Dalia S, Merhi B, Nemr S, Zarrabi A, Mitri J.

Leuk Res. 2012 Jul;36(7):868-75. doi: 10.1016/j.leukres.2011.12.020.

PMID:
22285508
20.

Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.

Reagan JL, Rosmarin A, Butera JN, Nadeem A, Schiffman FJ, Sikov WM, Winer E, Mega AE.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1075-80. doi: 10.1007/s00280-011-1702-0.

PMID:
21761371
Items per page

Supplemental Content

Loading ...
Support Center